Movement Alert｜WuXi XDC Rises 3.1% in Regular Trading, Buyback Execution and Sector Recovery Boost Sentiment

Market Focus06-01

On June 1, WuXi XDC rose 3.1% in regular trading, trading at HKD 55.4 per share, with trading volume of HKD 42.63 million, extending a rebound from prior sessions of weakness.

On the news front, the company disclosed that its professional trustee purchased 5.702 million shares on the open market between May 19 and May 29, representing approximately 0.45% of total issued shares, at a total cost of approximately HKD 327 million and an average purchase price of HKD 57.3 per share. All funds were sourced from the company's own financial resources. Combined with parent WuXi Biologics' previously announced buyback plan of up to USD 400 million, the WuXi group's aggregate buyback scale reaches USD 500 million. Guotai Junan International maintains an Overweight rating on the stock with a target price of HKD 84.38, citing strong growth prospects in the ADC pipeline. Within the Life Sciences Tools and Services sector, WuXi Biologics rose 5.64%, reflecting a broad recovery in sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195728847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195728847","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Rises 3.1% in Regular Trading, Buyback Execution and Sector Recovery Boost Sentiment","media":"Market Focus","content":"<p><p>On June 1, WuXi XDC rose 3.1% in regular trading, trading at HKD 55.4 per share, with trading volume of HKD 42.63 million, extending a rebound from prior sessions of weakness.</p><p>On the news front, the company disclosed that its professional trustee purchased 5.702 million shares on the open market between May 19 and May 29, representing approximately 0.45% of total issued shares, at a total cost of approximately HKD 327 million and an average purchase price of HKD 57.3 per share. All funds were sourced from the company's own financial resources. Combined with parent WuXi Biologics' previously announced buyback plan of up to USD 400 million, the WuXi group's aggregate buyback scale reaches USD 500 million. Guotai Junan International maintains an Overweight rating on the stock with a target price of HKD 84.38, citing strong growth prospects in the ADC pipeline. Within the Life Sciences Tools and Services sector, WuXi Biologics rose 5.64%, reflecting a broad recovery in sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Rises 3.1% in Regular Trading, Buyback Execution and Sector Recovery Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Rises 3.1% in Regular Trading, Buyback Execution and Sector Recovery Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, WuXi XDC rose 3.1% in regular trading, trading at HKD 55.4 per share, with trading volume of HKD 42.63 million, extending a rebound from prior sessions of weakness.</p><p>On the news front, the company disclosed that its professional trustee purchased 5.702 million shares on the open market between May 19 and May 29, representing approximately 0.45% of total issued shares, at a total cost of approximately HKD 327 million and an average purchase price of HKD 57.3 per share. All funds were sourced from the company's own financial resources. Combined with parent WuXi Biologics' previously announced buyback plan of up to USD 400 million, the WuXi group's aggregate buyback scale reaches USD 500 million. Guotai Junan International maintains an Overweight rating on the stock with a target price of HKD 84.38, citing strong growth prospects in the ADC pipeline. Within the Life Sciences Tools and Services sector, WuXi Biologics rose 5.64%, reflecting a broad recovery in sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1195728847","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195728847","pubTimestamp":1780278769,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, WuXi XDC rose 3.1% in regular trading, trading at HKD 55.4 per share, with trading volume of HKD 42.63 million, extending a rebound from prior sessions of weakness.On the news front, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动向提示|无锡XDC常规交易上涨3.1%，回购执行和行业复苏提振人气","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On June 1, WuXi XDC rose 3.1% in regular trading, trading at HKD 55.4 per share, with trading volume of HKD 42.63 million, extending a rebound from prior sessions of weakness.On the news front, the company disclosed that its professional trustee purchased 5.702 million shares on the open market between May 19 and May 29, representing approximately 0.45% of total issued shares, at a total cost of approximately HKD 327 million and an average purchase price of HKD 57.3 per share. All funds were sourced from the company's own financial resources. Combined with parent WuXi Biologics' previously announced buyback plan of up to USD 400 million, the WuXi group's aggregate buyback scale reaches USD 500 million. Guotai Junan International maintains an Overweight rating on the stock with a target price of HKD 84.38, citing strong growth prospects in the ADC pipeline. Within the Life Sciences Tools and Services sector, WuXi Biologics rose 5.64%, reflecting a broad recovery in sector sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195728847","isCrawlerRequest":true}